Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study - Kaku, K; Watada, H; Iwamoto, YTofogliflozin 003 Study Group (Cardiovasc Diabetol, 2014)
et al.,